Moreover, increasing evidence has indicated that aberrant lipid droplet accumulation in CRC with KRAS and BRAF mutations is associated with a poor response to anti-EGFR therapy (erlotinib), implying drug-resistant status in BRAF-mutated tumors is closely related to lipid metabolism (12, 13). The gene discussed is BRAF; the disease is colorectal carcinoma.